Brief: Kiromic BioPharma Announces First Patient Dosed In Phase 1 Study Evaluating Deltacel
14/12/2023 13:31
Dec 14 (Reuters) - Kiromic Biopharma Inc KRBP.PK :
* KIROMIC BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
STUDY
EVALUATING DELTACEL™ FOR THE TREATMENT OF NON-SMALL CELL LUNG
CANCER
* KIROMIC BIOPHARMA - INITIAL TOLERABILITY AND SAFETY DATA
FROM
FIRST PATIENT EXPECTED BY YEAR-END, WITH PRELIMINARY EFFICACY
RESULTS BY END OF JAN 2024
* KIROMIC BIOPHARMA INC - COMPANY EXPECTS THAT DELTACEL-01
CLINICAL TRIAL WILL START ENROLLING PATIENTS AT TWO ADDITIONAL
CLINICAL SITES IN EARLY 2024
Source text for Eikon: ID:nBw5b8Flsa
Further company coverage: KRBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site